Head and Neck Cancer UK – Patient Survey
The Head and Neck Cancer Coalition, of which Oracle Cancer Trust is a founding member, recently published it’s first Head and Neck Cancer UK Patient Survey.
A new survey has shed light on the experience of Head and Neck Cancer patients in the UK and how their treatment could be improved. The Head and Neck Cancer Coalition has released a report titled ‘Head and Neck Cancer in the UK: Patients, healthcare professionals and landscape analysis’, which was supported by Merck.
The study was conducted with the aim of understanding the perspective of Head and Neck Cancer patients throughout their treatment journey. It surveyed patients, carers, and healthcare professionals to gain insights into the challenges they face and how they believe the healthcare system could be improved.
The report found that patients experienced significant physical and emotional side effects during treatment, which affected their quality of life. They also encountered communication problems during their care, as well as limited access to support services.
In particular, the report highlighted the need for better patient education and information about the disease and the available treatment options. Patients also called for more support for their carers, who play an important role in their treatment.
The report recommends several solutions to improve the experience of Head and Neck Cancer patients, including a new patient-centred model of care delivery, better patient education and support, and greater emphasis on long-term follow-up care.
Overall, the ‘Head and Neck Cancer in the UK’ report provides a valuable insight into the experience of patients with this disease and offers a roadmap for how we can improve their care, ultimately leading to better outcomes for patients and their families.
Cancer Care: Why Mental Health Support Must Be Part of Every Cancer Journey
Oracle Head & Neck Cancer UK is proud to support the Daily Express Cancer Care campaign, a powerful series that shines a light on the often unseen emotional toll of cancer – and the urgent need for better psychological support for everyone affected. The campaign published over the past three weeks featured voices from across…
Ground-breaking blood test shows promise for early detection of head & neck and other hard-to-screen cancers
A new large-scale trial has found that the blood-based screening test known as Galleri test can detect more than 50 types of cancer – including cancers of the head and neck, which currently have no routine screening programme – and may significantly boost early diagnosis. The trial showed that, when used alongside existing screening methods,…
2 Minutes to Save Your Life: Oracle Launches HeadNeckCheck Campaign for Make Sense Week
This Make Sense Week (15-20 September), the European-wide head and neck cancer awareness initiative, Oracle Head & Neck Cancer UK, is championing both prevention and early detection – recognising that stopping cancer before it starts is just as vital as catching it early. Two Ways to Fight Cancer This Week Prevention Today: Head and neck…
Leadership update
After four successful years as CEO, Tamara Kahn has transformed Oracle into a respected national voice for head and neck cancer patients. She established a national presence, created a four-pillar RACE strategy (Research, Awareness, Collaboration and Patient/Community Engagement) and built strong policy influence. With these foundations now firmly in place, Tamara will transition from her…
Finding Light in Adversity: Seven inspiring stories through head and neck cancer
A new collection of patient stories from Oracle Head and Neck Cancer UK reveals how individuals facing head and neck cancer have discovered unexpected sources of strength, purpose and even joy during their treatment and recovery. The seven contributors share remarkably similar themes despite their unique journeys. Almost all emphasise the power of maintaining a…
NHS to fast-track patients with head and neck cancer into cancer vaccine trial
Patients with advanced head and neck cancers in England will be fast-tracked into a trial of a new cancer vaccine, as the NHS expands its world-leading trial ‘match-making’ service. The investigational cancer vaccine uses mRNA technology to help the immune system recognise and kill cancer cells containing human papillomavirus proteins. More than 100 patients with advanced head…
World Head and Neck Cancer Awareness Day 2025: The HPV Vaccine Could Save Your Life
27th July 2025 This World Head and Neck Cancer Awareness Day, Oracle Head and Neck Cancer UK has a simple but urgent message: HPV vaccination saves lives. With HPV-related head and neck cancers having doubled in the past 20 years, the charity is using today to remind the public that these devastating cancers are preventable…
Data from the National Disease Registration Service on HPV associated and HPV independent oropharyngeal squamous cell carcinoma
The Get Data Out Programme from the National Disease Registration Service (NDRS), part of NHS England, has published statistics on incidence, routes to diagnosis and treatment for patients diagnosed with oropharyngeal cancer in England by human papillomavirus (HPV) status. To our knowledge this is the first time data on oropharyngeal cancer by HPV status has…
Join Us for an Evening of Research, Impact, and Conversation
Research & Impact EveningDate: Monday 28th April 2025Time: 6:00 PM – 8:30 PMVenue: Skyline, Tower Suites, 100 Minories, London EC3N 1JY A Celebration of Research Join us for a meaningful and action-focused evening where we’ll be diving into some of the big conversations around head and neck cancer – especially those linked to HPV (human…
What the Rare Cancers Bill Means for Head & Neck Cancer
14 March marked a crucial moment for research into rare cancers, as the Rare Cancers Bill took another significant step toward becoming law! Dr. Scott Arthur, a Labour MP, introduced this legislation in Parliament to drive much-needed research into cancers affecting fewer than 1 in 2000 people in the UK – including many types of…